CDEK by Data4ThePeople
Sign in Sign up
← All organizations

Amicus Therapeutics

For profitContributed to NMEWebsite ↗

Also known as: Amicus CD LLC | AmicusTherapeutics | Amicus Therapeutics | Amicus Therapeutics, Inc. | Amicus Therapeutics US, LLC | AMICUS THERAPS US | AMICUS THERAP US

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 3

First clinical trial

Sep 1, 2005

First marketed drug

Aug 10, 2018

First NDA

Aug 10, 2018

Last known activity

Oct 31, 2025

Acquired by Biomarin on Dec 19, 2025

Timeline

2000s

  1. Feb 4, 2002

    Amicus Therapeutics— Founded

2010s

  1. Nov 1, 2013

    Callidus Biopharma— Acquired

  2. Aug 31, 2015

    Scioderm, Inc.— Acquired

  3. Aug 10, 2018

    migalastat— Marketing Organization

  4. Aug 10, 2018

    migalastat— NDA Organization

  5. Aug 10, 2018

    migalastat— NDA Secondary Org

  6. Sep 25, 2018

    Celenex— Acquired

2020s

  1. Dec 19, 2025

    BiomarinBiomarin— Acquired By

Drugs by trial phase (16 distinct, 40 trials)

Phase 2 (3 own, 0 via acquisition)

Phase 1 (1 own, 0 via acquisition)

Other trials (0 own, 1 via acquisition)

Indications

Approved for

Studied for

Marketed drugs (3)

Subsidiaries (3 direct, 3 total across the full acquisition tree)

Recent trials (50)

Details

Founded
Cranbury, NJ, US Feb 4, 2002
First NDA
Aug 10, 2018
Last known activity
Oct 31, 2025

Designations held

  • Orphan drug
  • Fast track
  • Priority review
  • Breakthrough therapy
  • Accelerated approval